vaccine sold brand names among others viral vector vaccine prevention developed united kingdom oxford university britishswedish company using vector modified chimpanzee adenovirus vaccine given intramuscular injection studies carried showed efficacy vaccine preventing symptomatic beginning days following first dose second study scotland found symptomatic infection second dose vaccine effective alpha variant lineage delta variant lineage vaccine stable refrigerator temperatures good safety profile side effects including injectionsite pain headache nausea generally resolving within rarely anaphylaxis may occur uk medicines healthcare products regulatory agency mhra reports million vaccinations april rare cases around people vaccine associated increased risk blood clots combination low levels blood platelets embolic thrombotic events according european medicines agency april total cases extremely rare blood clots recorded among million people vaccinated european economic area percentage december vaccine first approved use uk vaccination first vaccination outside trial administered january vaccine since approved several medicine agencies worldwide european medicines agency australian therapeutic goods administration provisional approval february approved emergency use listing world health organization january billion doses vaccine released countries countries limited use elderly people higher risk severe illness due concerns rare side effects vaccine younger vaccine used provide protection infection virus order prevent adults aged years medicine administered two ml us fl oz doses given intramuscular injection deltoid muscle upper arm initial course consists two doses interval weeks doses world health organization recommends interval weeks doses optimal august evidence third booster dose needed prevent severe disease healthy preliminary data study brazil million individuals january june indicate effectiveness infection hospitalization death similar age groups protection outcomes significantly reduced aged older attributable vaccine generally considered effective estimate lower limit confidence effectiveness generally expected slowly decrease preliminary data suggest initial twodose regimen effective symptomatic disease caused omicron variant week regimen two doses vaccine followed booster dose moderna vaccine initially effective symptomatic disease caused omicron weeks effectiveness drops moderna vaccine remains effective severe disease hospitalization vaccine administered people capillary leak common side effects clinical trials usually mild moderate got better within days vomiting diarrhoea fever swelling redness injection site low levels blood platelets occurred less enlarged lymph nodes decreased appetite dizziness sleepiness sweating abdominal pain itching rash occurred less increased risk rare potentially fatal thrombosis thrombocytopenia syndrome tts associated mainly younger female recipients analysis vigibase reported embolic thrombotic events vaccination moderna pfizer vaccines found temporally related incidence cases per million anaphylaxis allergic reactions known side effects european medicines agency ema assessed cases anaphylaxis around million vaccinations united capillary leak syndrome possible side effect european medicines agency ema listed guillainbarr√© syndrome rare side effect vaccine added warning product additional side effects include tinnitus persistent ringing ears paraesthesia unusual feeling skin tingling crawling sensation hypoaesthesia decreased feeling sensitivity especially vaccine viral vector vaccine containing modified replicationdeficient chimpanzee adenovirus containing coding sequence spike protein along tissue plasminogen activator tpa leader adenovirus called replicationdeficient essential genes required replication deleted replaced gene coding spike protein however hek cells used vaccine manufacturing express several adenoviral genes including ones required vector following vaccination adenovirus vector enters cells releases genes form dna transported cell nucleus thereafter cells machinery transcription dna mrna translation spike approach use adenovirus vector deliver spike protein similar approach used johnson johnson vaccine russian sputnik v protein interest spike protein protein exterior virus enables sarstype coronaviruses enter cells following vaccination production coronavirus spike protein within body cause immune system attack spike protein antibodies tcells virus later enters manufacture vaccine virus propagated hek cell lines purified multiple times completely remove cell vaccine costs around per dose december tweet belgian budget state secretary revealed european union eu would pay per dose new york times suggesting lower price might relate factors including investment vaccine production infrastructure march vaccine active substance produced several sites astrazeneca claiming established sites uk sites oxford keele bottling finishing sites include serum institute india halix site leiden approved ema march joining three sites approved vaccine arose collaboration oxford universitys jenner institute vaccitech private company spun university financing oxford sciences innovation google ventures sequoia capital among first batch vaccine produced clinical testing developed oxford universitys jenner institute oxford vaccine group collaboration italian manufacturer advent srl located team led sarah gilbert adrian hill andrew pollard teresa lambe sandy douglas catherine february jenner institute agreed collaboration italian company advent srl production batch doses vaccine candidate clinical originally oxford intended donate rights manufacture market vaccine drugmaker wanted gates foundation urged oxford find large company partner get vaccine market university backed offer may uk government encouraged oxford work astrazeneca company based europe instead merck co usbased company guardian reported initial partner germanbased merck group government ministers also concerns vaccine manufactured us would available uk according anonymous sources wall street journal financial considerations oxford spinout companies may also played part decision partner initially notforprofit licensing agreement signed university astrazeneca plc may billion doses potential supply secured uk reserving access initial million doses furthermore us reserved million doses well authority perform phase iii trials us collaboration also granted uk government funding us government funding support development june us national institute allergy infectious diseases niaid confirmed third phase trials vaccine would begin july june astrazeneca announced covax program equitable vaccine access managed financed cepi gavi spent secure million doses vaccine distributed lowincome underdeveloped preliminary data study reconstructed funding vaccine indicates funding least public almost uk government departments british american scientific institutes european commission july astrazeneca partnered iqvia accelerate timeframe clinical trials planned conducted august astrazeneca announced begun enrolment adults usfunded latestage clinical trials vaccine candidate halted worldwide september astrazeneca investigated possible adverse reaction occurred trial participant trials resumed september astrazeneca oxford along uk regulators concluded safe astrazeneca later criticised refusing provide details potentially serious neurological side effects two trial participants received experimental vaccine trials resumed uk brazil south africa india us resume clinical trials vaccine due separate investigation food drug administration surrounding patient illness triggered clinical hold according us department health human services hhs secretary alex results phase iiiii trial showed immunity lasts least one year single medical source november first interim data released oxford university astrazeneca vaccines ongoing phase iii interim data reported efficacy based combined results different groups participants given different dosages decision combine results two different dosages met criticism questioned results astrazeneca responded criticism agreeing carry new multicountry trial using lower dose led full publication interim results four ongoing phase iii trials december allowed regulators scientists begin evaluating vaccines december report showed days second dose beyond hospitalisations severe disease received vaccine compared cases control groups rate serious adverse events balanced active control groups suggested active vaccine pose safety concerns beyond rate experienced general population one case transverse myelitis reported days seconddose administered possibly related vaccination independent neurological committee considering likely diagnosis idiopathic shortsegment spinal cord demyelination two cases transverse myelitis one vaccine group control group considered unrelated subsequent analysis published february showed efficacy preventing symptomatic beginning days following first dose increasing second dose given weeks however results show protection asymptomatic following one beginning days following timely administration second dose different duration first dose depending trials results showed efficacy preventing symptomatic infection uk arm evaluated asymptomatic infections participants inconclusive prevention asymptomatic efficacy higher greater intervals doses peaking around second dose given weeks longer preliminary results another study participants years age showed delaying second dose weeks increases resulting immune response booster third dose given least six months later produces strong immune response booster dose may necessary alleviates concerns body would develop immunity vaccines viral vector would reduce potency annual march astrazeneca released interim results phase iii trial conducted us showed efficacy preventing symptomatic efficacy preventing severe disease next day national institute allergy infectious diseases niaid published statement countering results may relied outdated information may provided incomplete view efficacy astrazeneca later revised efficacy claim review september astrazeneca shows efficacy rate us study effectiveness first dose vaccines related hospitalisation scotland based national prospective cohort study million people december february participants vaccinated study given vaccine first dose vaccine associated vaccine effect hospitalisation days postvaccination combined results vaccinated participants whether showed significant vaccine effect prevention hospitalisation comparable restricting analysis aged years majority participants age given march university oxford announced start phase clinical trial investigate efficacy intranasal spray first country issue temporary emergency approval vaccine uk medicines healthcare products regulatory agency mhra began review efficacy safety data november followed approval use december becoming second vaccine approved use national vaccination bbc reported first person receive vaccine outside clinical trials vaccinated january european medicines agency ema began review vaccine january stated press release recommendation could issued agency january followed european commission deciding conditional marketing authorisation within january ema recommended granting conditional marketing authorisation people years age recommendation accepted european commission prior approval across eu hungarian regulator unilaterally approved vaccine instead waiting ema october conditional marketing authorisation converted standard january vietnamese ministry health approved astrazeneca vaccine use becoming first vaccine approved vaccine since approved number noneu countries including dominican el sri regulatory authorities emergency usage respective countries south korea granted approval astrazeneca vaccine february thus becoming first vaccine approved use country regulator recommended twoshot regimen used adults including elderly noting consideration needed administering vaccine individuals years age due limited data demographic clinical day world health organization issued interim guidance recommended astrazeneca vaccine adults strategic advisory group experts also considered use variants present concluded need recommend february government regulatory authorities australia february canada february granted approval temporary use november vaccine approved use february vaccine rollout south africa suspended researchers university witwatersrand released interim nonpeerreviewed data suggested astrazeneca vaccine provided minimal protection mild moderate disease infection among young bbc reported february katherine obrien director immunisation felt really plausible astrazeneca vaccine could meaningful impact beta variant lineage particularly preventing serious illness report also indicated deputy chief medical officer england jonathan vantam said witwatersrand study change opinion astrazeneca vaccine rather likely effect severe disease beta south african government subsequently cancelled use astrazeneca march austria suspended use one batch vaccine two people blood clots vaccination one total four cases blood clots identified batch million although causal link vaccination several countries including france also halted vaccine rollout following days waiting ema finish safety review triggered casescitation needed april ema concluded safety review concluded unusual blood clots low blood platelets listed rare side effects reaffirming overall benefits following announcement eu countries resumed use vaccine limiting use elderly people higher risk severe march norwegian government temporarily suspended vaccines use awaiting information regarding potential adverse effects april norwegian institute public health recommended government permanently suspended vaccination astrazeneca due rare severe incidents low platelet counts blood clots haemorrhages since case norway risk dying vaccination astrazeneca vaccine would higher risk dying disease particularly younger time norwegian government announced decision wait final decision establish expert group provide broader assessment safety astrazeneca janssen may expert committee also recommended suspending use finally may months initial prime minister norway announced government decided completely remove astrazeneca vaccine norwegian coronavirus immunisation programme people first offered another coronavirus vaccine second march german ministry health announced use vaccine people aged result recipientspecific younger patients could still given astrazeneca vaccine discretion doctors individual risk analysis thorough april danish health authority suspended use danish health authority said vaccines available next target groups lowerrisk population weighed fact known risk severe adverse effects vaccination astrazeneca even risk absolute terms study found decisions suspend vaccine led increased vaccine hesitancy across west even countries suspend october conditional marketing authorisation converted standard despite continued authorsation eu countries stopped administration vaccine end needed initial quick uptake number doses administered remained million since october march canadas national advisory committee immunization naci recommended distribution vaccine suspended patients age naci chairwoman caroline quachthanh stated risk blood clots higher younger patients naci needed evolve recommendations new data becomes available canadian provinces subsequently announced would follow april three confirmed cases blood clotting tied vaccine canada doses administered beginning april amid major third wave virus several canadian provinces announced would backtrack naci recommendation extend eligibility astrazeneca vaccine residents young years old including alberta british columbia ontario saskatchewan quebec also extended eligibility residents naci guidance recommendation affect formal approval vaccine health canada adults stated april updated warnings vaccine part ongoing review potential risk events rare benefits vaccine protecting outweigh potential april citing current state supplies mrnabased vaccines new data naci issued recommendation vaccine offered patients young years old benefits outweigh risks patient wish wait mrna beginning may multiple provinces announced would suspend use astrazeneca vaccine citing either supply issues blood clotting risk provinces stated planned use astrazeneca vaccine outstanding second june naci issued guidance citing safety concerns well european studies showing improved antibody response recommending mrna vaccine administered second dose patients received astrazeneca vaccine first march indonesia halted rollout vaccine awaiting safety guidance world health resumed using vaccine june australia revised recommendations rollout vaccine recommending pfizer comirnaty vaccine used people aged years person already received first dose astrazeneca vaccine astrazeneca vaccine still used people aged years benefits likely outweigh risks person person made informed decision based understanding risks benefits consultation medical initially approving use astrazeneca vaccine malaysian health authorities removed vaccine countrys mainstream vaccination programme due public concerns astrazeneca vaccines distributed designated vaccination centres public register vaccine voluntary basis doses initial batch vaccine fully booked three half hours registration opened residents state selangor federal territory kuala second batch doses offered residents states selangor penang johore sarawak federal territory kuala lumpur total doses reserved previously waitlisted registrants doses taken senior citizens grace period remaining doses offered aged completely booked within march european medicines agency ema stated indication vaccination cause observed clotting issues listed side effects time according ema number thromboembolic events vaccinated people higher seen general march cases thromboembolic events reported among almost million people vaccinated european economic uks mhra also stated million doses administered confirmed reported blood clots caused vaccine vaccinations would march stated causal relationship shown vaccinations astrazeneca confirmed march examining million people vaccinated vaccine evidence increased risk blood clots particular country company reported march across eu uk events deep vein thrombosis events pulmonary embolism reported among given vaccine much lower would expected occur naturally general population march german paulehrlich institute pei reported million vaccinations seven cases cerebral vein thrombosis conjunction deficiency blood platelets according pei number cases cerebral vein thrombosis vaccination statistically significantly higher number would occur general population similar time reports prompted pei recommend temporary suspension vaccinations ema completed review world health organization issued statement march regarding astrazeneca vaccine safety signals still considers benefits vaccine outweigh potential risks recommending vaccinations march ema announced around million people received vaccine general blood clotting rates normal identified seven cases disseminated intravascular coagulation eighteen cases cerebral venous sinus causal link vaccine proven ema said would conduct analysis recommended informing people eligible vaccine fact possibility may cause rare clotting problems ema confirmed vaccines benefits outweighed march ema released updated product according ema cases blood clots occur naturally month eu risk blood clots statistically higher vaccinated population ema noted causes increased risk development blood clots vaccine would lower risk formation blood clots even cases causal link italy resumed vaccinations emas remaining european countries following suit resuming astrazeneca inoculations shortly reassure public vaccines safety british french prime ministers boris johnson jean castex vaccinated front media shortly restart astrazeneca vaccination campaigns april ema issued direct healthcare professional communication dhpc dhpc indicated causal relationship vaccine blood clots thrombosis combination low blood platelets thrombocytopenia plausible identified rare side effect according ema rare adverse events occur around vaccinated study published april researchers genomics united kingdom consortium ampheus project oxford vaccine trial group indicated vaccine showed somewhat reduced efficacy infection alpha variant lineage efficacy absolute terms alpha versus despite researchers concluded vaccine remained effective preventing symptomatic infection variant vaccinated individuals infected symptomatically typically shorter duration symptoms less viral load thereby reducing risk following identification notable variants concern concern arose mutation present beta gamma variants lineages could evade protection given february collaboration working adapt vaccine target expectation modified vaccine would available months booster given people already completed twodose series original june astrazeneca published press release confirming undergoing phase iiiii trials variant vaccine candidate new vaccine would based current vaxzevria adenoviral vector platform modified spike proteins based beta lineage phase iiiii trials saw volunteers participating uk south africa brazil poland parallel dosing current oxfordastrazeneca vaccine variant vaccine september vaccine candidate still undergoing phase iiiii trials intent switch vaccine approved government regulators particularly government thailand delivery additional million doses astrazeneca vaccine agreed december clinical trial registered examine heterologous primeboost vaccination course consisting one dose vaccine followed sputnik light based vector days suspensions due rare cases blood clots march canada several european countries recommended receiving different vaccine second dose despite lack clinical data efficacy safety heterologous combinations experts believe may boost immunity several studies begun examine june preliminary results study participants showed heterologous primeboost vaccination course consisting one dose vaccine followed one dose vaccine produced strongest cell activity antibody level almost high two doses pfizerbiontech vaccine reversal order resulted cell activity half potency oneseventh antibody levels latter still five times higher two doses lowest cell activity observed homologous courses doses july study participants found heterologous primeboost vaccination course consisting one dose vaccine followed one dose moderna vaccine produced similar level neutralizing antibodies cell responses increased spikespecific cytotoxic cells compared homologous course consisting two doses moderna oxford university astrazeneca collaboration seen potential lowcost vaccine onerous storage series events including deliberate undermining astrazeneca vaccine geopolitical purposes eu eu member states including miscommunication reports supply difficulties responsibility due eu mishandling vaccine misleading reports inefficacy adverse well highprofile european vaccine dispute public relations disaster brussels member opinion one academic led increased vaccine vaccine key component backed covax vaccines global access ema mhra continuing state benefits vaccine outweigh possible side million doses vaccine administered eueea authorization june agreements access vaccines began signed may uk priority first million doses trials proved successful final agreement signed end may astrazeneca agreed provide million doses us billion implying cost per astrazeneca spokesman said funding also covers development clinical also reached technology transfer agreement mexican argentinean governments agreed produce least million doses distributed throughout latin america active ingredients would produced argentina sent mexico completed june emergent biosolutions signed million deal manufacture doses astrazeneca vaccine specifically us market deal part trump administrations operation warp speed initiative develop rapidly scale production targeted vaccines end catalent would responsible finishing packaging june whos covax vaccines global access facility made initial purchases million doses company low middleincome also astrazeneca serum institute india reached licensing agreement independently supply billion doses oxford university vaccine middle lowincome countries including later september funded grant bill melinda gates foundation covax program secured additional million doses per august astrazeneca concluded agreement eu supply million doses eu select european economic area eea member european commission took negotiations started inclusive vaccines alliance group made france germany italy netherlands june november tripartite agreement signed government bangladesh serum institute india beximco pharma bangladesh agreement bangladesh ordered million doses vaccine serum beximco per hand indian government given million doses bangladesh gift also produced serum serum supplied million doses tripartite agreement first two months bangladesh supposed receive million doses per month received shipments march result rollout vaccine disrupted supply situation became complicated second dose million citizens uncertain india halts getting second dose right time likely reduce effectiveness vaccination program addition several citizens bangladesh expressed doubts effectiveness bangladesh looking alternative vaccine sources india isnt supplying vaccine according timeline thailands agreement november million doses would cover million approximately population first lot expected delivered end public health minister indicated price paid per astrazeneca thailand explained january controversy price country paid depended production cost differences supply chain including manufacturing capacity labour raw material january thai cabinet approved talks ordering another million thai fda approved vaccine emergency use siam bioscience company owned vajiralongkorn receive technological capacity manufacture million doses year export also november philippines agreed buy million reportedly worth around million approximately per december south korea signed contract astrazeneca secure million doses vaccine reportedly equivalent worth signed thailand first shipment expected early january january vaccine remains review south korea disease control prevention astrazeneca signed deal south koreas sk bioscience manufacture vaccine products collaboration calls sk affiliate manufacture local global january south african government announced secured initial million doses serum institute india followed another doses however south african government subsequently cancelled use vaccine selling supply african countries switched vaccination program use janssen january astrazeneca announced event european union approved vaccine astrazeneca initial supplies would lower expected due production issues novasep belgium million previously predicted million doses would delivered eu march interview italian newspaper la repubblica astrazenecas ceo pascal soriot said delivery schedule doses eu two months behind schedule mentioned low yield cell cultures one largescale european analysis published guardian also identified apparently low yield bioreactors belgium plant noted difficulties setting form process variable yields often result eu imposed export controls vaccine doses controversy erupted whether doses diverted uk whether deliveries northern ireland would february shipment vaccine accra ghana via covax made first country africa receive vaccines via early bureau investigative journalism found south africa paid double rate european commission uganda paid according higher education statistics agency data oxford received million windfall vaccine academic vaccine marketed brand name covishield serum institute name vaccine changed vaxzevria european union march vaxzevria astrazeneca vaccine vaccine astrazeneca manufactured february development team working adapting vaccine effective relation newer variants redesigning vaccine relatively quick process switching genetic sequence spike manufacturing setup small scale trial also required adapted vaccine might available